检索结果-南通市图书馆

More than eight years＇ hands-on experience with the novel long-acting parenteral testosterone undecanoate

Asian Journal of Andrology 2007年第3期9卷 291-297页

作者： Farid Saad Axel Kamischke Aksam Yassin Michael Zitzmann Markus Schubert ffiedrich jockenhovel HermannM. Behre Louis Gooren Eberhard Nieschlag Bayer-Schering Department of Men＇s Health Berlin Germany Gulf Medical College School of Medicine Ajman United Arab Emirates Institute of Reproductive Medicine of the University of Munster Munster Germany Department of Urology Segeberger Kliniken Norderstedt Germany Innere Medizin Klinikum der Universitiit zu Koln Koln Germany Evangelisches Krankenhaus Herne Herne Germany Andrology Unit Department of Urology Martin-Luther UniversitT Halle Germany Department of Endocrinology Andrology Section Vrije Universiteit Medical Center Amsterdam the Netherlands

Testosterone （T） as a compound for treatment of T deficiency has been available for almost 70 years, but the pharmaceutical formulations have been less than ideal. Traditionally, injectable T esters have been used for treatment, but they generate supranormal T levels shortly after the 2-3 weekly injection interval. T levels then decline very rapidly, becoming subnormal during the days preceding the next injection. The rapid fluctuations in plasma T are subjectively experienced as disagreeable. T undecanoate （TU） is a new injectable T preparation with a considerably better pharmacokinetic profile. After two initial injections separated by a 6-week interval, the following intervals between two injections are generally 12 weeks, eventually amounting to a total of four injections per year. Plasma T levels with this preparation are nearly always in the range of normal men, as are its metabolic products estradiol and dihydrotestosterone （DHT）. It reverses the effects of hypogonadism on bone and muscle and metabolic parameters, and on sex functions. It is suitable for male contraception. Its safety profile is excellent because of the continuous normalcy of plasma T levels. No polycythemia has been observed and no adverse effects on lipid profiles. Prostate safety parameters are well within reference limits. TU is a valuable treatment option of androgen deficiency.

关键词： testosterone treatment testosterone undecanoate pharmacokinetic profile clinical efficacy side effects sexual dysfunction male contraception

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：